| Gene symbol | PROM1 | Synonyms | AC133, CD133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4p15.32 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | prominin 1 | ||||
| Gene symbol | EGFR | Synonyms | ERBB, ERBB1, ERRP, HER1, NISBD2, PIG61, mENA | Type of gene | protein-coding |
| Chromosome | 7 | Map location | 7p11.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | epidermal growth factor receptor | ||||
| Gene symbol | EPHA2 | Synonyms | ARCC2, CTPA, CTPP1, CTRCT6, ECK | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p36.13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | EPH receptor A2 | ||||
| Gene symbol | ERBB2 | Synonyms | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | erb-b2 receptor tyrosine kinase 2 | ||||
| Gene symbol | IL13RA2 | Synonyms | CD213A2, CT19, IL-13R, IL13BP | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq23 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | interleukin 13 receptor subunit alpha 2 | ||||
| GTO ID | GTC0418 |
| Trial ID | NCT03423992 |
| Disease | Brain Glioma |
| Altered gene | EGFR|IL13RA2|HER2|EPHA2|CD133|GD2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas |
| Year | 2018 |
| Country | China |
| Company sponsor | Xuanwu Hospital, Beijing |
| Other ID(s) | Xuanwu hospital |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||